Business
Appointment of Joint Broker
Appointment of Joint Broker.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8605B\n Scancell Holdings Plc\n 15 June 2021\n \n \n \n 15 June 2021\n \n Scancell Holdings plc\n (\"Scancell\" or the \"Company\")\n \n \n Appointment of Joint Broker\n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces the appointment of Stifel Nicolaus Europe Limited as Joint Broker alongside Panmure Gordon, the existing Broker and Nominated Adviser, with immediate effect.\n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc\n \n \n +44 (0) 20 3727 1000\n \n \n \n \n Dr John Chiplin, Executive Chairman\n \n \n \n \n \n \n \n Dr Cliff Holloway, CEO\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)\n \n \n +44 (0) 20 7886 2500\n \n \n \n \n Freddy Crossley/Emma Earl (Corporate Finance)\n \n \n \n \n \n \n \n Rupert Dearden (Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stifel Nicolaus Europe Limited (Joint Broker)\n \n \n +44 (0) 20 7710 7600\n \n \n \n \n Nicholas Moore/Ben Maddison (Healthcare Investment Banking)\n \n \n \n \n \n \n \n Nick Adams (Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n FTI Consulting\n \n \n +44 (0) 20 3727 1000\n \n \n \n \n Simon Conway/Natalie Garland-Collins\n \n \n \n \n \n \n \n About Scancell\n \n \n Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications and development of a vaccine for COVID-19.\n \n \n \n \n \n ImmunoBody® vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target and eliminate cancer cells. These cancer vaccines have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. The Directors believe that this platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.\n \n \n \n \n \n · \n SCIB1, Scancell's lead product, is being developed for th...